Antiviral medicine

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly a medicine for treatment of viral disease, including HIV infection (AIDS and HIV related diseases). The antiviral medicine is a solution containing fullerene-polyhydropolyaminocaproic acid and dimethyl sulfoxide in the following component content per ampoule: fullerene-polyhydropolyaminocaproic acid 50 mg, dimethyl sulfoxide up to 0.5 ml. The medicine is intended for intramuscular or intravenous (drip-feed) administration, and dissolved in 20 ml of water for intramuscular administration, while the variant for intravenous administration includes additionally 20 ml of 0.9% sodium chloride solution per 1 ampoule.

EFFECT: obtaining antiviral medicine for treatment of virus diseases including HIV infection.

 

The invention relates to pharmaceutical industry and relates to the creation of tools for the treatment of viral diseases, including HIV infection (AIDS and HIV-associated diseases).

Famous complex of separate preparations of the day the treatment of viral infections, consisting of interferon, which is administered rectally in the form of an aqueous solution, and vitamins E and C, which is administered in the form of oil solution intramuscularly in parallel with interferon (ed. mon. The USSR №1530189, 1988).

Small synthetic antiviral agents - Medinan, methisazone, find a limited prophylactic use, such as iodoxuridine, oksolina, are applied topically in viral diseases of the skin, and the toxicity of the first very high (Pharmacology. M.: Medicine, 1981, s-401).

Known drugs have long latency period, which creates the risk of exposure of the organism to the development of the maximum protective effect of interferon and, in addition, a known antiviral agents have a certain toxicity.

The present invention is the creation of facilities possessing antiviral activity, especially effective in the treatment of HIV infection.

To solve the problem proposed antiviral agent, executed in the form of a solution containing the fullerene-oligotrophication acid and dimethylsulfoxide in the following ingredients in 1 ampoule:

fullerene-polyhydroxyalkanoate acid50 mg
the sulfoxideto 0.5 ml

The tool is intended for intramuscular or intravenous (drip) introduction for intramuscular dissolved in 20 ml of water, and when administered intravenously to the patient further comprises a 0.9% solution of sodium chloride at the rate of 20 ml 1 vial.

Fullerene-polyhydroxyalkanoate acid powder is dark brown almost black color with no odor. The connection is not soluble either in water or chloroform, but soluble in dimethyl sulfoxide (100 mg/ml), so it is soluble in water and in chloroform.

Most chemical reactions with the fullerenes are not selective, which complicates the synthesis of individual compounds. Therefore, in the product are present as position isomers, and compounds that differ in the number of attached amino acids.

Derivative of fullerene and aminocaproic acid with the number of connected groups of at least 2 General formula:

With60Hn[NH(CH2)5C(O)O-]n,

where C60- fullerene core,

[NH(CH2)5C(O)O-] - aminocapronic anion

The solution for injection and infusion are prepared according to the adopted technology in the pharmaceutical industry for 0.5 ml in ampoules of glass lighting with notches or ring fault.

Preparation for intramuscular injection and intravenous infusion can be used only in diluted form.

The solution for parenteral administration must not be stored.

Way of application and dose.

Adult drug administered intramuscularly or intravenously (drip) in doses of 50-100 mg once a day rate of 5-10 injections per month depending on the diagnosis and severity of the disease.

For intramuscular injection the contents of the capsules dissolve in 2.0 ml of water for injection.

For intravenous use solution of the product prepared ex tempore of the concentrate by adding 20 ml of 0.9% sodium chloride solution to each vial. The drug is administered by intravenous infusion at a rate of 3 ml (50-60 drops) per minute.

The drug can be used intranasal; in one nostril buried in 3-5 drops of the drug, dissolved in 2.0 ml of water for injection, 5 times a day.

The solution for intranasal use, store in the refrigerator for no more than one week.

It is assumed that because the drug does not penetrate into the cell, there is no danger of its interaction with other antiviral drugs.

Mark what should be excluded drugs cause of drug sensitization: antibiotics, nonsteroidal anti-inflammatory agents.

Not be used in conjunction with drugs that affect leucopoiesis; exclude myelodepression drugs, tiazidove diuretics, estrogen and ethanol inhibit the production of platelets.

The drug was tested in the Institute of Virology. Dijanoveckog Russian Academy of medical Sciences and clinical infectious diseases hospital No. 2 (Nizhny Novgorod).

Tests in vitro and clinical trials have shown:

The drug is active against HIV / AIDS and HIV-associated diseases.

The use of the drug in the treatment of patients with HIV infection leads to a decrease in viral load in lymphocytes and serum, the increase in the number of CD-4 cells, prevention of opportunistic infections that occur on the background of immunodeficiency.

The use of the drug in the treatment of patients with herpes viral infections, low immune status leads to an increase in the duration of remission. The drug is able to prevent the formation of lesions, if taken when the first symptoms of recurrent herpes simplex. The drug helps to eliminate pain, reduce the number of lesions, accelerate their disappearance.

Before therapy is a complete clinical examination of a patient with a binding definition in the anti-shudder performance of viral load in plasma and number T-4 lymphocytes. When making the decision to start treatment should take into account the desire of the patient to be treated, the degree of immunosuppression, which is judged by the number of T-4 lymphocytes, and the progression of the disease.

Treatment of patients with HIV-infection drug should start, if there are clinical symptoms indicative of immunodeficiency.

Herpes viral infections: herpes simplex skin and mucous membranes in patients with immune system disorders; genital herpes (primary and recurrent), herpes zoster, chicken pox.

When the treatment was regularly controlled renal function and liver, determined the content of the formed elements of the blood, and carried out the biochemical and hematological blood tests at least once per month. In case of deterioration of the hematological parameters were specified dose or stop treatment.

In some cases, after applying the solution intranasally may experience a momentary feeling weak burns. May cause local irritation of the mucous membranes, disappearing after drug withdrawal.

1. Antiviral agent, characterized in that it is made in the form of a solution containing the fullerene-polyhydroxyalkanoate acid and dimethylsulfoxide in the following ingredients in 1 ampoule:

fullerene-polyhydroxyalkanoate acid50 mg
the sulfoxideto 0.5 ml

2. The tool according to claim 1, which is intended for intramuscular or intravenous drip infusion.

3. The tool according to claim 1, which is for intramuscular dissolved in 20 ml of water for injection.

4. The tool according to claim 1, which when administered intravenously to the patient further comprises a 0.9% solution of sodium chloride at the rate of 20 ml 1 vial.



 

Same patents:

Antiviral medicine // 2333752

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly medicine for treatment of virus diseases, including HIV infection (AIDS and HIV-related diseases). The antiviral medicine is a 1% ointment containing fullerene-polyhydropolyaminocaproic acid as active substance and auxiliary substances of dimethylsulfoxide, water-free lanolin and Vaseline in the following amount (g): fullerene-polyhydropolyaminocaproic acid 1.0, diemthylsulfoxide 10.0, water-free lanolin 10.0, Vaseline up to 100.0.

EFFECT: obtaining antiviral medicine for treatment of virus diseases, including HIV infection.

Antiviral medicine // 2333751

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly medicine for treatment of virus diseases, including HIV infection (AIDS and HIV-related diseases). The antiviral medicine is a suppository containing fullerene-polyhydropolyaminocaproic acid and auxiliary substances of dimethylsulfoxide, water-free lanolin or vegetable oil selected out of olive, peach, bumpkin seed oil, and base selected out of W-35 or H-15 vitepsol, cacao butter, solid fat, in the following amount per one 2 g suppository: fullerene-polyhydropolyaminocaproic acid 5-20 mg, diemthylsulfoxide 50-200 mg, water-free lanolin or vegetable oil 20-100 mg, the rest being the base.

EFFECT: obtaining antiviral medicine for treatment of virus diseases, including HIV infection.

FIELD: chemistry.

SUBSTANCE: invention relates to the new isoflavon derivative of tectorigenine compound of formula (II) , where R1 represents H, NH2 or SO3M; R2 represents OR'; R3 represents H or -CH2NR"; wherein R' represents H, -CH2COONa or -CH2CH2NMe2; NR" represents or -NMe2; M represents H, Na, K or N+H(CH2CH2OH)3, it also relates to virus inactivating agent having this derivative as an active ingredient and to the method for preparation of the injections on its basis.

EFFECT: developing of production method for the injections on basis of tectorigenine.

20 cl, 10 tbl, 2 dwg,10 ex

FIELD: medicine; veterinary.

SUBSTANCE: medicine for bird influenza treatment includes activated-potentiated form of antibodies to bird alpha, beta and gamma interferon obtained by multiple sequential cultivation and external affection by homeopathic technology.

EFFECT: improved efficiency of treatment.

4 cl, 3 ex

FIELD: medicine; pediatrics.

SUBSTANCE: by the first vaccination of 3-18 months old children vaccination is performed at least over 60 days after their arrival to Far North regions from other climatic zones.

EFFECT: high vaccination efficiency due to taking in consideration processes of child organism adaptation to a change of climatic zones.

7 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention claims application of starches substituted by quarterly ammonium groups with substitution degree of 0.4 to 3.0 with the help of a linker, in infection diseases treatment. Suppression of 1 type herpes virus replication by the claimed starches is demonstrated, in comparison to zero antivirus effect of non-modified starches. Minimal inhibiting concentration for staphylococci and mycobacteria is 5-60 g/l.

EFFECT: efficient infection disease treatment by the claimed starches.

5 cl, 7 tbl

FIELD: chemistry, pharmaceuticals.

SUBSTANCE: invention pertains to compounds with formula (I), their pharmaceutical salts or N-oxide used as an inhibitor to replication and/or proliferation of HCV, to the method of inhibiting replication or proliferation of hepatitis C virion using formula (I) compounds, as well as to pharmaceutical compositions based on them. The compounds can be used for treating or preventing infections, caused by hepatitis C virus. In general formula (I) cycle B is an aromatic or non-aromatic ring, which contains two heteroatoms, where X and Y, each is independently chosen from C, CH, N or O, under the condition that, both X and Y are not O and that, both X and Y are not N; U and T represent C; Z represents -CH-; A represents N or -CR2-; B represents -CR3-; D represents N or -CR4-; E represents N or -CR5-; G represents N or -CR6-; J represents N or -CR14-; K represents -CR8-; L represents N or -CR9-; M represents N or -CR10-; R2 and R6, each is independently chosen from a group, consisting of hydrogen, halogen, C1-C6alkyl, substituted C1-C6alkyl, C1-C6alkoxy, C1-C6substituted alkoxy, C1-C6alkoxycarbonyl, cycloheteroalkyl, substituted cycloheteroalkyl, -O-carbamoil, substituted -O-carbamoil, halogen C1-C6alkyl, diC1-C6alkylamino, substituted diC1-C6alkylamino and sylye ethers, where cycloheteroalkyl is a 3-7-member ring, containing 1-2 heteroatoms, chosen from N and O, under the condition that, one of R2 and R6 is not hydrogen; R3 and R5, each is independently chosen from a group, consisting of hydrogen, halogen; R4 represents hydrogen; R7 represents - NR11C(O)R12; R8, R9, R10 and R14, each is independently represents hydrogen; R11 represents hydrogen, C1-C6alkyl; and R12 is chosen from a group, consisting of halogen C1-C6alkyl; where each substituted group is substituted with one or more groups, chosen from -Q, -R40, -OR40, -C(O)R40, -C(O)OR40, where each Q independently represents halogen, R40 and R41 are independently chosen from a group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, under the condition that: (i) at least one of A, D, E, G, J, L or M represents N; (ii) not more than one of A, D, E or G represents N; and (iii) not more than one of J, L or M represents N.

EFFECT: obtaining pyridyl-substituted heterocycles for treating and preventing infections, caused by hepatitis C virus.

33 cl, 85 dwg, 101 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. Medicinal agent applied for prevention and treatment of bird viral influenza is represented with polystibuim. Polystibium inhibits infectious activity of influenza virus.

EFFECT: development of effective method applied for treatment and prevention of bird influenza.

6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products and concerns combination for HIV-infection treatment, containing (a) therapeutically effective amount of HIV-protease inhibitor by formula or its pharmaceutically accepted salt or ester and (b) effective amount of rhytonavir or its pharmaceutically accepted salt or ester. Besides, method of improved pharmacokinetics of HIV-protease inhibitor by formula (4) or its pharmaceutically accepted salt or ester, including introduction to an individual requiring such treatment, therapeutically effective amount of rhytonavir or its pharmaceutically accepted salt or ester with therapeutically effective amount of specified HIV-protease inhibitor by formula (4) is described.

EFFECT: offered combination has synergetic action if taken in any molar ratios.

33 cl, 6 dwg, 9 tbl, 4 ex

FIELD: bioengineering.

SUBSTANCE: novel polynucleotide is invented which is produced from the nucleotide sequence of the IFNα-17 gene, containing the single nucleotide polymorphism SNP g771c. Also, the novel polynucleotide is invented which is derived from the natural protein IFNα-17 of the wild type containing SNP G45R.

EFFECT: can be used for producing effective therapeutic agent with antiviral, antiproliferative and/or immunomodulating activity.

13 cl, 5 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns drugs, particularly a water-soluble granulate and its application for treatment of pain, inflammation, fever and respiratory diseases of animals, the granulate containing meloxicam, linking agent, sugar or sweetener, carrier, salt-forming component to form meglumine, sodium, potassium or ammonium meloxicam salt, optional aromatiser, and other optional auxiliary substances. The invention also concerns method for obtaining the claimed granulate.

EFFECT: possibility of optical control of completely dissolved active substance due to absolute solubility of the granulate in water.

16 cl, 4 ex

FIELD: medicine; pharmacology.

SUBSTANCE: method consists in additing water-soluble salt of calcium to the solution of calcium gluconat representing calcium Sodium lactatum, a mass ratio of calcium gluconat : calcium Sodium lactatum 10 : (1-3). Mixing of the said components is carried out at heating to 80°C.

EFFECT: increased storage stability.

3 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention represents a stable liquid composition containing an anti-IgE-antibody or a monoclonal anti-IgE-antibody, arginin-HCI, Histidinum, polysorbate and can be used for hypodermic introduction to a patient, as necessary.

EFFECT: optimum highly concentrated compositions of antibodies with low viscosity and turbidity.

39 cl, 14 ex, 7 tbl, 10 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, particularly to drug preparation of deanol aceglumate. An injection drug formulation is proposed, containing ingredients as follows: deanol aceglumate, sugars (sorbitol, xylitol, and others), aminoacetic versene, optionally succinic acid, malic acid, and N-dimethylaminoethanol. It was demonstrated, that the injection drug formulation of deanol aceglumate shows neuroprotective action and can be applied to acute cerebral circulation injury, preventing from cerebral ischemia damage.

EFFECT: generation of stable and sterile injection drug formulation of deanol aceglumate, suitable for applying in diabetes cases.

3 cl, 4 ex, 2 tbl, 2 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: injection dosage form for acute stroke treatment includes noopeot in therapeutically effective amount as reactant, and as adjuvants, at least one selected from group including lactose, saccharose, polyvinyl alcohol, polyvinylpyrrolidone, sorbite, mannitol, glycine, aqueous solutions, fatty oils, ethyl oleate, glycerine, ethyl alcohol, propylene glycol, polyethylene oxide 400, benzyl benzoate, benzyl alcohol and other adjuvants allowed for medical application. Injection dosage form meets all requirements of State Pharmacopeia, XI edition. Medical product Noopept (N-phenyl acetyl-L- prolyl glycine ethyl ether) as injection dosage form provides high nootropic and neuroprotective activity applied to models of extensive ischemic stroke and hemorrhagic stroke.

EFFECT: stabile storage ability and high bioavailability.

8 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: described oil solution for injection to patient is characterised by the fact that it includes 25-200 mg/ml of the first component which is ethonogestrel ether and 50-400 mg/ml of the second component which the fatty acid ether with chain length within C6 to C12 and 7-alpha-methyl-19-nortestosterone, where progesterone ether and androgen ether are dissolved in ethylundecanoate. Besides, related introduction device is described.

EFFECT: high level of predisposition to treatment implying infrequent painless introduction without by-effects and local reactions.

2 cl, 2 tbl, 6 ex, 15 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to injection solution based on agents of vitamin B group and lydocaine giving beneficial effect on inflammatory and degenerative nervous and motor system diseases, having analgesic action, providing increase of blood flow and blood formation. Injection solution contains the following components: thiamine chloride, pyridoxine hydrochloride, cyanocobalamin, lydocaine hydrochloride, sodium hydroxide, benzetonium chloride, trilon B and injection water. Injection solution is non-toxic and can be applied for patients suffering from depressed liver function and needy for medical treatment with this agent.

EFFECT: solution is non-toxic.

1 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: invention can be applied for post-injection medicine safety express evaluation when injected into soft and liquid tissues. Period of post-injection resorption in specified tissue is preevaluated by analogy with the same volume of 0.9% sodium chloride. Then medicine solution ready-for-injection is settled on freshly made raw ovalbumin inside of transparent test tube, and ovalbumin transparency over medium boundaries is visually evaluated through transmitted light during period of medicamental infiltrate post-injection resorption within selected tissue. Whitish opacification ring indicates low post-injection medicinal agent safety.

EFFECT: invention provides more rapid and improved examination of post-injection medicinal agent safety.

1 ex

FIELD: medicine, endocrinology, hormones.

SUBSTANCE: invention describes an aqueous injection solution of antagonist of releasing-hormone luteinizing hormone (LHRH) containing gluconic acid, a filling agent and, optionally, a surfactant. LHRH antagonist is chosen from group of substances: cetrorelix, teverelix, D-63153 (Ac-D-Nal-pCl-Z-Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-Nle-Arg-Pro-D-Ala-NH2), ganipelix, abarelix, antide or azalin B wherein gluconic acid is taken as delta-lactone in the above equimolar amount with respect to the amount of LHRH antagonist, and mannitol is used a filling agent. LHRG antagonist shows significantly improved solubility and can be prepared in higher concentrations and enhanced bioavailability. Also, tendency of LHRH antagonist to aggregation is reduced significantly.

EFFECT: improved and valuable properties of antagonist.

7 cl, 1 tbl, 3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes agent that possesses the nootropic activity and comprises dimephosphone as an active substance. Medicinal agent in form of an aqueous solution comprises additionally citric acid and lithium carbonate in the following ratio of components, wt.-%: dimephosphone, 15.0-30.0; lithium carbonate, 0.5-5.0; citric acid, 3.0-4.0, and deionized water, up to 100. Medicinal agent in form of syrup comprises the following composition, wt.-%: dimephosphone, 3.0-5.0; lithium carbonate, 1.0-1.2; citric acid, 4.0-5.0, and 64% sugar syrup, 89.0-92.0. Variants of the invention are syrup with the increased concentration of dimephosphone, and syrup comprising glycine additionally. Novel medicinal agents show physiological pH values elicited in the broad range of concentrations, stability of solutions in dilution, pleasant taste that simplified their using in pediatrics.

EFFECT: improved and valuable pharmaceutical properties of drug.

5 cl, 5 tbl, 1 dwg, 12 ex

Antiviral medicine // 2333752

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly medicine for treatment of virus diseases, including HIV infection (AIDS and HIV-related diseases). The antiviral medicine is a 1% ointment containing fullerene-polyhydropolyaminocaproic acid as active substance and auxiliary substances of dimethylsulfoxide, water-free lanolin and Vaseline in the following amount (g): fullerene-polyhydropolyaminocaproic acid 1.0, diemthylsulfoxide 10.0, water-free lanolin 10.0, Vaseline up to 100.0.

EFFECT: obtaining antiviral medicine for treatment of virus diseases, including HIV infection.

Up!